Therapeutic effects of alendronate on bone erosion and atrophy in a patient with rheumatoid arthritis and hepatitis C virus infection

Journal of Rheumatology

Volumn 35, Issue 11, 2008, Pages 2284-2286

  Soejima, Makoto ^a   Kawaguchi, Yasushi ^a   Hara, Masako ^a   Saito, Seiji ^a   Kamatani, Naoyuki ^a   Yamanaka, Hisashi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADULT; BONE ATROPHY; BONE EROSION; CASE REPORT; CLINICAL FEATURE; HAND RADIOGRAPHY; HEPATITIS C; HUMAN; KIDNEY FUNCTION TEST; LETTER; LIVER FUNCTION TEST; MALE; MONOTHERAPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; ALENDRONATE; ARTHRITIS, RHEUMATOID; ATROPHY; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; HEPATITIS C, CHRONIC; HUMANS; MALE;

EID: 56449088540     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080201     Document Type: Letter

References (10)

1. Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 1999;42:415-20.
2. Ikari K, Momohara S. Images in clinical medicine. Bone changes in rheumatoid arthritis. N Engl J Med 2005;353:e13.
3. Phillips K, Aliprantis A, Coblyn J. Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis. Drugs Aging 2006;23:773-9.
4. Harada H, Nakayama T, Nanaka T, Katsumata T. Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis. Inflamm Res 2004;53:45-52.
5. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
6. Palazzi C, Olivieri I, Cacciatore P, Pennese E, D'Amico E. Management of hepatitis C virus-related arthritis. Exp Opin Pharmacother 2005;6:27-34.
7. Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. BioDrugs 2004;18:269-78.
8. Szekanecz Z, Koch AE. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007;3:635-43.
9. Sims NA, Green JR, Glatt M, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 2004;50:2338-46.
10. Jarrett SJ, Conaghan PG, Sloan VS, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006;54:1410-4.